


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claim 1 (original): Deoxynojirimycin analogue, or a pharmaceutically acceptable salt thereof, having the general structure (I)

(I)



wherein

R₁-R₅ each independently comprise H or (CH₂)_nCH₃ or X;

R₆ comprises H, CH₂OH or CH₂OX; M is 0 or 1;

N is 0-9;

a, b, c, d, e are chiral centra having an R or S configuration;

and X comprises a large hydrophobic moiety and a spacer, whereby the hydrophobic moiety is linked through the spacer to the nitrogen atom or carbon atom concerned, and wherein the large hydrophobic moiety is derived from a polycyclic alcohol containing three or more rings each sharing two or more carbon atoms with another ring and is capable of inserting in lipid bilayers.

Claim 2 (original): Deoxynojirimycin analogue, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein the large hydrophobic moiety is linked to said nitrogen atom of the deoxynojirimycin by means of a spacer comprising an alkoxy polyalkylene or polyalkylene chain of from 3 to 8 carbon atoms.

Claim 3 (currently amended): Deoxynojirimycin analogue, or a pharmaceutically acceptable salt thereof, according to claim 1 ~~or 2~~, wherein the large hydrophobic moiety is derived from a compound selected from the group consisting of adamantanemethanol, cholesterol, β -cholestanol, adamantanol and 9-hydroxyphenanthrene.

Claim 4 (currently amended): Deoxynojirimycin analogue, or a pharmaceutically acceptable salt thereof, according to ~~any one of claims 1-3~~ claim 1, having the ido-configuration.

Claim 5 (original): Deoxynojirimycin analogue comprising ido-N-(5-adamantane-1-yl-methoxy pentyl)deoxynojirimycin, or a pharmaceutically acceptable salt thereof.

Claim 6 (currently amended): Deoxynojirimycin analogue according to ~~any one of claims 1-5~~ claim 1 for use in the treatment of a disease involving increased levels of glucosylceramide and glucosphingolipids.

Claim 7 (currently amended): Deoxynojirimycin analogue according to ~~any one of~~
~~claims 1-5~~ claim 1 for use in the treatment of a disease involving increased levels of
glucosylceramide, glucosphingolipids and glucosidases.

Claim 8 (original): Dexynojirimycin analogue according to claim 6 for use in the
treatment of Gaucher disease.

Claim 9 (original): Dexynojirimycin analogue according to claim 6 for use in the
treatment of an inflammatory disease.

Claim 10 (original): Dexynojirimycin analogue according to claim 6 for use in the
treatment of hyperpigmentation and/or inflammatory skin conditions.

Claim 11 (original): Dexynojirimycin analogue according to claim 6 for use in the
treatment of a fungal disease.

Claim 12 (original): Dexynojirimycin analogue according to claim 6 for use in the
treatment of overweight and obesity.

Claim 13 (original): Dexynojirimycin analogue according to claim 6 for use in the
treatment of lysosomal storage disorders.

Claim 14 (original): Dexynojirimycin analogue according to claim 6 for use in the treatment of melanoma and other tumors.

Claim 15 (original): Dexynojirimycin analogue according to claim 6 for use in the treatment of a microbacterial infection.

Claim 16 (original): Dexynojirimycin analogue according to claim 7 for use in the treatment of insulin resistance.

Claim 17 (currently amended): Pharmaceutical composition comprising a deoxynojirimycin analogue, or pharmaceutically acceptable salt thereof, according to ~~any one of claims 1-5~~ claim 1 and a pharmaceutically acceptable carrier.

Claim 18 (original): Method of treatment of an individual suffering from a disease selected from the group consisting of insulin resistance, Gaucher disease, inflammatory diseases, hyperpigmentation and/or inflammatory skin conditions, overweight and obesity, lysosomal storage disorders, fungal diseases, melanoma and other tumors, and microbacterial infections, comprising administering to said individual an effective amount of the pharmaceutical composition according to claim 17.